Because a characteristic feature of SSc is fibroblast activation that results in fibrosis and inflammation, Liang et al., studied the anti-fibrosis activity of BEZ235 (dual inhibitor of PI3K/mTOR) and rapamycin (mTORC1 inhibitor) in activated fibroblasts and in two murine models of SSc. Here, MTOR is linked to systemic sclerosis.